Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 8,586 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 8,586 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $24.42, for a total value of $209,670.12. Following the sale, the chief operating officer directly owned 21,874 shares in the company, valued at $534,163.08. This trade represents a 28.19% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

NASDAQ:CSTL traded up $0.10 during mid-day trading on Monday, hitting $24.21. 187,688 shares of the stock traded hands, compared to its average volume of 397,864. Castle Biosciences, Inc. has a 12-month low of $14.59 and a 12-month high of $44.28. The company has a quick ratio of 6.53, a current ratio of 6.75 and a debt-to-equity ratio of 0.02. The company has a market cap of $734.29 million, a PE ratio of -55.02 and a beta of 1.00. The business’s 50-day moving average price is $21.54 and its 200 day moving average price is $28.56.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.49) EPS for the quarter, hitting the consensus estimate of ($0.49). The company had revenue of $84.23 million during the quarter, compared to analyst estimates of $79.23 million. Castle Biosciences had a negative return on equity of 2.77% and a negative net margin of 3.78%. On average, analysts expect that Castle Biosciences, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

Institutional investors have recently made changes to their positions in the company. Federated Hermes Inc. bought a new position in Castle Biosciences during the 4th quarter valued at about $26,000. Kemnay Advisory Services Inc. bought a new stake in Castle Biosciences during the fourth quarter valued at approximately $35,000. Jones Financial Companies Lllp increased its holdings in Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after buying an additional 2,648 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Castle Biosciences by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock worth $55,000 after acquiring an additional 297 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Castle Biosciences by 63.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock worth $57,000 after purchasing an additional 976 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Robert W. Baird cut their price target on shares of Castle Biosciences from $44.00 to $43.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Roth Mkm began coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They set a “buy” rating and a $40.00 price target for the company. Canaccord Genuity Group dropped their target price on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a report on Monday, April 20th. Wall Street Zen downgraded Castle Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, KeyCorp set a $35.00 price objective on shares of Castle Biosciences in a report on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.43.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.